Onconova Therapeutics

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).

Traws Pharma Announces New Employee Inducement Grants

NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further characterize the mechanism of rigosertib at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place April 5-10, 2024 in San Diego, CA.

Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024

Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compared to approved CDK4/6 inhibitors Data support the potential use of narazaciclib in breast and ovarian cancers Narazaciclib progressing towards RP2D and preparation for registrational studies, with a planned update in H1 2024 NEWTOWN, Pa., Dec. 08, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preclinical data highlighting narazaciclib's multi-kinase profile, broad anti-tumor activity and increased anti-tumor immunity, compared to palbociclib and other CDK4/6 inhibitors, in a poster presented at the San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023.

Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's

NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D.

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Victor Moyo - Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Meena Arora - VP of Global Medical Affairs & Research and Development, Conference Call Participants Edouard Mullarky - Guggenheim Partners Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Welcome to Onconova Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call.

Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript

Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational preparations for the narazaciclib program and the rigosertib trial plan expected in the first half of 2024 Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023 NEWTOWN, Pa.

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its third quarter 2023 financial results on Tuesday, November 14, 2023.

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models

Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL

Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company expanded its leadership team with the naming of Dr. Victor Moyo as Chief Medical Officer (CMO), and the addition of Meena Arora as Vice President, Global Medical Affairs and Research and Development (R&D).

Onconova Expands Leadership Team with Two Key Appointments

Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that a late-breaking abstract reporting the use of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB) associated with advanced/metastatic squamous cell carcinoma (SCC) will be presented in the Late Breaking News session at the European Academy of Dermatology and Venereology (EADV) 2023 Congress taking place October 11-14 in Berlin, Germany.

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO Dr. Victor Moyo - Consultant Chief Medical Officer Mark Guerin - Chief Operating Officer and CFO Fred Frullo - Vice President, Regulatory Affairs and Quality Assurance Conference Call Participants Edouard Mullarky - Guggenheim Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter [Technical Difficulty] Dr. Steve Fruchtman Sarah, excuse me, you are coming in and out and I don't know if other people hear.

Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript

Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa

Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting

Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Steven Fruchtman - President and Chief Executive Officer Michael Saunders - Interim Chief Medical Officer Mark Guerin - Chief Operating Officer and Chief Financial Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright Ahu Demir - Ladenburg Thalmann Robert LeBoyer - Noble Life Science Partners Operator Ladies and gentlemen, thank you for standing by.

Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript

Onconova Therapeutics, Inc. (ONTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.20 per share a year ago.

Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates

NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) --   Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended March 31, 2023, and provided a business update.

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m.

Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer

Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023

Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023

Applied Therapeutics Inc

Cipher Mining

Analysts say these are penny stocks to buy but do you agree? The post 3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks To Buy According To Analysts, Targets Up To 1,029%

Aethlon Medical

Mangoceuticals Inc

Nordic American Tankers

Tingo Group Inc

Hot penny stocks to watch this week. This is a significant week for earnings, and mega-cap tech names will headline what's sure to be a volatile week. Next week, the action continues with the upcoming Fed meeting and another rate hike decision.

5 Hot Penny Stocks To Watch With The Stock Market Down This Week

Nuburu Inc

Clearmind Medicine Inc

NovaBay Pharmaceuticals

SAITECH Global Corp

Penny stocks news sparks momentum in the stock market today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 5 With Big News Today

NEWTOWN, Pa., April 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that its Chief Medical Officer (CMO) Mark Gelder, M.D., recently passed away unexpectedly. Michael Saunders, M.D., has been appointed the interim Chief Medical Officer of the Company.

Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder

Collaboration builds off clinical data demonstrating rigosertib's activity against PLK1 and may inform a precision medicine approach towards rigosertib's evaluation in new indications

News for Onconova Therapeutics Stock (ONTX)